Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
Licensing Agreements 13
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14
Akcea Therapeutics Inc – Key Employees 17
Akcea Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Strategy And Business Planning 19
Sep 06, 2017: Akcea Therapeutics Establishes Canadian Subsidiary 19
Financial Announcements 20
Aug 06, 2018: Akcea reports financial results and highlights for second quarter 2018 20
May 03, 2018: Akcea Reports Financial Results and Highlights for First Quarter 2018 22
Feb 26, 2018: Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 24
Nov 06, 2017: Akcea Reports Financial Results and Highlights for Third Quarter 2017 26
Aug 08, 2017: Akcea Reports Financial Results and Highlights for Second Quarter 2017 28
Corporate Communications 30
Oct 08, 2018: Akcea announces changes to Board of Directors 30
Jun 05, 2018: Akcea Therapeutics Names Dr. Richard Moscicki As Board Director 31
Apr 17, 2018: Sarah Boyce Joins Akcea Therapeutics As President And Member Of Board Of Directors 32
Sep 05, 2017: Akcea Expands Leadership Team in Preparation for First Commercial Launch 33
May 09, 2017: Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors 35
Mar 28, 2017: Akcea Therapeutics Announces Three Additions to Board of Directors 36
Product News 37
10/16/2017: Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome 37
07/11/2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 38
05/02/2018: Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS 39
03/21/2018: MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS) 40
03/12/2018: Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo 41
02/28/2018: Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome 43
02/15/2018: Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome 44
Product Approvals 45
Nov 15, 2017: Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS 45
Oct 10, 2017: Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) 46
Sep 12, 2017: Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada 47
Aug 31, 2017: Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA 49
Jul 27, 2017: Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency 51
Clinical Trials 52
Apr 26, 2018: Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions 52
Jan 05, 2018: Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease 53
Oct 31, 2017: Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx 55
Aug 08, 2017: Akcea Provides Update on AKCEA-APOCIII-LRx 56
Mar 30, 2017: Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease 57
Mar 06, 2017: Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome 58
Other Significant Developments 60
Jun 12, 2018: Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14
Akcea Therapeutics Inc, Key Competitors 16
Akcea Therapeutics Inc, Key Employees 17
List of Figures
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9